New CEO Will Ready Synta For Commercialization As Ganetespib Begins Phase III In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi’s North American head of pharmaceuticals will move into the top spot at Synta in September, as the company prepares to transition from a clinical-stage to a commercial company. Lead candidate ganetespib has begun Phase III in advanced NSCLC, with final data expected in 2016.